Yunkang Group's revenue for the
six
months ended in Dec. 2023 was HK$453.5 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$975.1 Mil.
Yunkang Group's Revenue per Share for the
six
months ended in Dec. 2023 was HK$0.75.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$1.59.
Warning Sign:
Yunkang Group Ltd revenue per share has been in decline over the past 3 years.
During the past 12 months, the average Revenue per Share Growth Rate of Yunkang Group was -78.10% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -11.70% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 24.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 6 years, Yunkang Group's highest 3-Year average Revenue per Share Growth Rate was 81.00% per year. The lowest was -11.70% per year. And the median was 45.30% per year.
Yunkang Group Revenue Historical Data
The historical data trend for Yunkang Group's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Yunkang Group's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Yunkang Group's Revenue Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Yunkang Group's Revenue distribution charts can be found below:
* The bar in red indicates where Yunkang Group's Revenue falls into.
Yunkang Group Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$975.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Yunkang Group (HKSE:02325) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Yunkang Group Revenue Related Terms
Thank you for viewing the detailed overview of Yunkang Group's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Yunkang Group Ltd is a medical operation service provider in China. The company has three major business lines namely covering diagnostic testing services for medical consortia, diagnostic outsourcing services, and non-medical institutions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:02325 has been successfully added to your 